Linalool has shown efficacy for symptoms such as reduction of anxiety, decreased inflammation, and analgesia (pain killing properties). It is often employed in aromatherapy and integrated into activities such as yoga and meditation.
Its sedative properties mean that, in proper doses, linalool may be effective in helping those suffering seizure disorders, such as epilepsy and Dravet Syndrome.
The multifaceted efficacy of this terpene means that it has been found to effectively treat a variety of conditions, from obesity to tobacco smoke-induced lung inflammation to the memory and cognitive loss associated with neurodegenerative diseases.
A 2016 study entitled “Linalool Reserves Neuropathological and Behavioral Impairments in Old Triple Transgenic Alzheimers Mice” that was published in the journal Neuropharmacology found that linalool may help slow, stop, and even reverse the cognitive decline associated with diseases such as Alzheimer disease and Parkinsons disease.
The researchers found this cognitive restorative efficacy to be enabled by the anti-inflammatory properties of linalool. The study concluded, “Our findings suggest that linalool reverses the histopathological hallmarks of [Alzhemiers] and restores cognitive and emotional functions via an anti-inflammatory effect. Thus, linalool may be an [Alzheimers] prevention candidate for preclinical studies.”
A 2007 study involving a placebo-controlled human trial with 54 participants entitled “Treatment with Lavender Aromatherpy Reduces Opioid Requirements of Morbidly Obese Patients” that was published in the journal Obesity Surgery revealed that linalool may be helpful to those attempting to decrease or eliminate their consumption of opioid painkillers, as well as those suffering obesity.
The study reports, “Significantly more patients in the Placebo group (PL) required analgesics for postoperative pain (22/27, 82%) than patients in the [linalool] group (12/26, 46%),” adding, “Moreover, the [linalool] patients required significantly less morphine postoperatively than PL patients.”